Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD and Efficacy of Cufence in Wilson’s Disease
2024-516431-27-00Phase 4Completed
- Sponsor
- Univar Solutions
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 4, open-label, single-arm trial of trientine in Wilson disease (WD), sponsored by Univar Solutions. Primary endpoints: Concentration of trientine in plasma, Trientine clearance (CL/F) and volume(s) of distribution (V/F) and 5 more. Started Sep 2024; status: completed.
02
Drugs
trientine
03
Conditions
Wilson disease (WD)
Beyond the preview
Go deeper on 2024-516431-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516431-27-00.